FDA Approves Ripretinib Tablets for Advanced Gastrointestinal Stromal Tumor

Ripretinib is now indicated for adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with 3 or more kinase inhibitor therapies.

Source: CancerNetwork - May 15, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news